Abstract 1492P
Background
The aim of this study was to investigate the LACE index to predict the risk of 30-day unplanned hospital readmission in patients receiving immunotherapy. Since hospitalisation is a common and costly condition, we evaluated this score in non-small cell metastatic lung cancer patients receiving immunotherapy.
Methods
Between January 2020 and December 2023, 157 patients with metastatic non-small cell lung cancer receiving immunotherapy in our center were screened. Patients who died during hospitalisation, patients admitted for chemotherapy and day care procedures, and subsequent hospitalisation within a month were excluded. LACE index model includes the length of hospitalization stay (L), acuity of the admission (A), comorbidities of patients (C), and the number of emergency department visits in the six months before admission (E). LACE index scores of the patients were calculated according to this model.
Results
A total of 72 metastatic non-small cell lung cancer patients hospitalised in our oncology inpatient clinic were included in the study. Thirty-five (48.6%) of the patients were over 65 years of age. Most of the patients had lung adenocarcinoma (n:49, 68.1%). Twenty-one (29.2%) patients had cranial metastases. Forty-four (61.1%) patients were hospitalised for palliative care and 28 (38.9%) were hospitalized due to infection. The median hospital stay of the patients was four days (min-max: 1- 30). The median LACE score of the patients was 11 (min-max: 6-16). Fourty-six (% 63.9) patients had a high LACE score, twenty-six were in the moderate group. Thirty (65.2%) of 46 patients with high LACE scores were readmitted to the hospital within 30 days. This rate was statistically significantly higher (p: 0.028) than the moderate group (n=10, 38.5%). While 45.7% of the patient group with a high LACE score died within 90 days, this rate was (26.9%) in the moderate patient group (p: 0.11).
Conclusions
The LACE index predicted one-month readmission in oncology patients receiving immunotherapy but was insufficient to predict death within 90 days. It can be considered as an easy-to-use index in patients receiving immunotherapy to predict readmission.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10